Efficacy of Immune Checkpoint Inhibitors in Elderly Cancer Patients

Immune checkpoint inhibitors have transformed the management of a broad range of malignancies by reinvigorating antitumour T-cell responses. In elderly patients, who represent a growing proportion of the cancer population, age-related immune alterations—collectively termed immunosenescence—pose unique challenges to the efficacy and safety of these therapies. While reductions in naïve T-cell output, diminished T-cell receptor diversity and altered cytokine profiles may attenuate therapeutic benefit, age-associated increases in tumour mutational burden and expression of inhibitory ligands such as PD-L1 can paradoxically enhance sensitivity to checkpoint blockade. Real-world evidence suggests that elderly individuals often experience comparable survival gains to younger cohorts but may exhibit distinct patterns of immune-related adverse events, tolerability, and therapy discontinuation rates. The integration of comprehensive geriatric assessment and biomarkers of immunocompetence has emerged as a means to personalise immunotherapy in older adults, balancing maximised clinical benefit with minimised toxicity. Globally, the optimisation of checkpoint inhibitor regimens for patients over 65 years holds promise for improving outcomes in an ageing demographic and for guiding equitable access to these life-prolonging treatments.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Efficacy of Immune Checkpoint Inhibitors in Elderly Cancer Patients publication trend

The graph below shows the total number of articles in efficacy of immune checkpoint inhibitors in elderly cancer patients across all publications each year (not limited to Nature Index journals).

Technical terms

Immune checkpoint inhibitors: Therapies that block regulatory pathways (e.g. PD-1, PD-L1, CTLA-4) to enhance T-cell–mediated tumour killing.

Immunosenescence: Age-related decline in immune function characterised by reduced naïve lymphocytes, skewed cytokine production and impaired memory responses.

Tumour mutational burden (TMB): The total number of non-synonymous mutations per coding area of a tumour genome, used as a predictive biomarker for immunotherapy response.

Progression-free survival (PFS): The length of time during and after treatment in which a patient’s disease does not worsen.

Overall survival (OS): The duration from treatment initiation until death from any cause, reflecting ultimate clinical benefit.

Comprehensive geriatric assessment: Multidimensional evaluation encompassing functional status, comorbidities and psychosocial factors to guide therapeutic decisions in older adults.

References

1. Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study. Cancer Letters (2024).
2. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. Journal for ImmunoTherapy of Cancer (2018).
3. Evaluating the impact of age on immune checkpoint therapy biomarkers. Cell Reports (2021).